AR038596A1 - Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus - Google Patents

Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus

Info

Publication number
AR038596A1
AR038596A1 ARP030100590A ARP030100590A AR038596A1 AR 038596 A1 AR038596 A1 AR 038596A1 AR P030100590 A ARP030100590 A AR P030100590A AR P030100590 A ARP030100590 A AR P030100590A AR 038596 A1 AR038596 A1 AR 038596A1
Authority
AR
Argentina
Prior art keywords
metapneumovirus
products
viruses
gene
virus
Prior art date
Application number
ARP030100590A
Other languages
English (en)
Spanish (es)
Original Assignee
Vironovative Bv
Medimmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vironovative Bv, Medimmune Vaccines Inc filed Critical Vironovative Bv
Publication of AR038596A1 publication Critical patent/AR038596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18341—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
ARP030100590A 2002-02-21 2003-02-24 Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus AR038596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35893402P 2002-02-21 2002-02-21

Publications (1)

Publication Number Publication Date
AR038596A1 true AR038596A1 (es) 2005-01-19

Family

ID=27766025

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP030100590A AR038596A1 (es) 2002-02-21 2003-02-24 Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus
ARP030100589A AR038595A1 (es) 2002-02-21 2003-02-24 Cepas de metaneumovirus y su uso en formulaciones de vacunas y como vectores para la expresion de secuencias antigenicas
ARP110102759A AR082426A2 (es) 2002-02-21 2011-07-29 Un virus recombinante de parainfluenza (piv)
ARP110102760A AR082427A2 (es) 2002-02-21 2011-07-29 Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP030100589A AR038595A1 (es) 2002-02-21 2003-02-24 Cepas de metaneumovirus y su uso en formulaciones de vacunas y como vectores para la expresion de secuencias antigenicas
ARP110102759A AR082426A2 (es) 2002-02-21 2011-07-29 Un virus recombinante de parainfluenza (piv)
ARP110102760A AR082427A2 (es) 2002-02-21 2011-07-29 Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus

Country Status (12)

Country Link
US (11) US7449324B2 (enExample)
EP (3) EP2327418A1 (enExample)
JP (4) JP4553589B2 (enExample)
KR (2) KR101076102B1 (enExample)
CN (2) CN101098958A (enExample)
AR (4) AR038596A1 (enExample)
AU (2) AU2003219837B2 (enExample)
CA (3) CA2477235A1 (enExample)
IL (2) IL163646A0 (enExample)
MX (1) MXPA04008088A (enExample)
TW (4) TWI405851B (enExample)
WO (2) WO2003072720A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094105A1 (en) 1998-04-24 2006-05-04 University Hospitals Of Cleveland Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
UA93981C2 (ru) * 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
CA2508378A1 (en) * 2002-12-02 2004-06-17 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
JP2007524372A (ja) * 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
JP2007525178A (ja) * 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP1713824A2 (en) * 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
AU2005318087B2 (en) * 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
US20060216700A1 (en) * 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8492097B2 (en) * 2006-04-24 2013-07-23 Diagnostic Hybrids, Inc. Compositions and methods for human metapneumovirus monoclonal antibodies
US20080213749A1 (en) * 2007-03-02 2008-09-04 Melanie Feola Compositions and methods for detecting human metapneumovirus
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
JP2010539093A (ja) * 2007-09-10 2010-12-16 インターベツト・インターナシヨナル・ベー・ベー イヌ、ネコ及びウマにおけるインフルエンザ感染を予防するための組成物及び方法
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20090165049A1 (en) * 2007-12-19 2009-06-25 United Video Properties, Inc. Methods and devices for presenting and interactive media guidance application
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
KR101073991B1 (ko) * 2009-10-27 2011-10-21 대한민국 국내사육 닭에서 유행하는 신규한 ｂ형 조류메타뉴모바이러스 ｓｃ1509주 및 이의 용도
WO2011097607A1 (en) * 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
NZ609952A (en) * 2010-11-10 2015-05-29 Leti Sl Lab Adjuvant fragments from leishmania species
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
EP2674491B1 (en) * 2011-02-08 2017-06-14 Mie University Method for producing virus vector for gene transfer
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
CN102676701B (zh) * 2012-06-11 2013-08-14 广东温氏食品集团股份有限公司 禽肺病毒通用型rt-pcr检测引物及检测方法
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
SMT202400297T1 (it) 2013-03-13 2024-09-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Proteine f del rsv pre-fusione e loro uso
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
EP2873728A1 (en) * 2013-11-18 2015-05-20 Institut Pasteur A subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
KR101577397B1 (ko) * 2014-01-15 2015-12-28 경북대학교 산학협력단 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트
MX387331B (es) * 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.
CA2974359A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof
EP3309251A4 (en) * 2015-06-12 2019-03-13 Mie University HUMAN PARAIN FLUENZA TYPE 2 VIRUS VIRUS VECTOR AND VACCINE
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh
MA52645B1 (fr) 2015-10-22 2022-06-30 Modernatx Inc Vaccins contre le virus respiratoire
CN109069611B (zh) 2016-03-29 2022-11-04 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN106282407A (zh) * 2016-08-11 2017-01-04 青岛易邦生物工程有限公司 一种b亚群禽肺病毒疫苗的效检方法
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3630173A1 (en) 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
WO2019055768A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS
FR3084079A1 (fr) 2018-07-23 2020-01-24 Universite Claude Bernard Lyon 1 Nouvelle souche virale attenuee et son utilisation en tant que vaccin
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
FR3089789B1 (fr) 2018-12-14 2022-05-27 Univ Claude Bernard Lyon Production de vaccins viraux sur une lignee cellulaire aviaire
US20220125909A1 (en) * 2019-02-11 2022-04-28 Emory University Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
CA3216466A1 (en) 2021-04-27 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing sars-cov-2 spike protein and its use
EP4351592A1 (en) 2021-06-09 2024-04-17 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
CN118302191A (zh) 2021-11-30 2024-07-05 圣诺菲·帕斯图尔公司 基于病毒载体的人偏肺病毒疫苗

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0413695B1 (en) 1988-04-22 1994-05-04 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3.
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5229285A (en) 1991-06-27 1993-07-20 Kikkoman Corporation Thermostable luciferase of firefly, thermostable luciferase gene of firefly, novel recombinant dna, and process for the preparation of thermostable luciferase of firefly
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
GB9501170D0 (en) 1994-03-23 1995-03-08 Secr Defence Luciferases
ATE175244T1 (de) 1994-04-19 1999-01-15 Stichting Centraal Lab Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahren
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
WO1997008342A1 (en) 1995-08-30 1997-03-06 Gentest Corporation Cytochrome p450 reporter gene
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
ES2109189B1 (es) 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
US5849036A (en) * 1996-03-29 1998-12-15 Zarate; Alfredo R. Vascular graft prosthesis
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
EP2112220A3 (en) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
CA2265554A1 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
GB9707486D0 (en) 1997-04-11 1997-05-28 Secr Defence Enzyme assays
US6136585A (en) * 1997-05-02 2000-10-24 Uab Research Foundation Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof
EP0981537B1 (en) * 1997-05-07 2007-07-18 The Cleveland Clinic Foundation An infectious clone for human parainfluenza virus type 3
BR9809456B1 (pt) * 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
US20030082209A1 (en) * 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
AU731663B2 (en) 1997-07-11 2001-04-05 Yale University Rhabdoviruses with reengineered coats
CN1273603A (zh) 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
WO2000020600A1 (en) 1998-10-05 2000-04-13 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
ATE367445T1 (de) 1999-05-18 2007-08-15 Dnavec Research Inc Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen
KR100940776B1 (ko) 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 사람-소 키메라 파라인플루엔자바이러스(ｐｉｖ) 백신
EP1200213B1 (de) 1999-07-29 2003-03-05 Hatebur Umformmaschinen AG Vorrichtung zur erzeugung einer hebe- und senkbewegung
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
MXPA01008108A (es) 1999-12-10 2004-11-12 Health Uso de virus de parainfluenza recombinante (pivs) como vectores para la proteccioncontra la infeccion y enfermedad provocadas por piv y otros patogenos humanos.
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6387586B1 (en) 2000-11-06 2002-05-14 Eastman Kodak Company High contrast visually adaptive radiographic film and imaging assembly for thoracic imaging
CA2797703A1 (en) 2000-11-28 2002-06-06 Medimmune, Llc Recombinant rsv virus expression systems and vaccines
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
EP1456398B1 (en) * 2001-11-21 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US7292593B1 (en) 2002-03-28 2007-11-06 Advanced Micro Devices, Inc. Arrangement in a channel adapter for segregating transmit packet data in transmit buffers based on respective virtual lanes
DE10221836A1 (de) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2003294533A1 (en) 2002-12-19 2004-07-14 Universite Laval Molecular methods and compositions for detecting and quantifying respiratory viruses
JP2007524372A (ja) * 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
JP2006519457A (ja) 2003-03-05 2006-08-24 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 光媒体における情報書き込み／消去用パワーパラメータを決定する装置及び方法
US7440195B2 (en) 2003-03-31 2008-10-21 Konica Minolta Camera, Inc. Zoom lens system and imaging device having the same
CA2521856A1 (en) 2003-04-08 2004-10-21 Coronovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
CA2523657A1 (en) 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2007525178A (ja) * 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
EP1533370A1 (en) 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
EP1548748A1 (en) 2003-12-17 2005-06-29 Interuniversitaire Microelectronica Centrum vzw ( IMEC) A method for making probes for atomic force microscopy
WO2005080991A1 (en) 2004-02-20 2005-09-01 Erasmus Universiteit Rotterdam Method to detect antigen-specific cytolytic activity
US8318423B2 (en) 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
EP2272950A3 (en) 2004-11-11 2011-07-20 Abbott Biologicals B.V. Defective influenza virus particles
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
US20060216700A1 (en) 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2006110214A2 (en) 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1748447B1 (en) 2005-07-28 2008-10-22 Interuniversitair Microelektronica Centrum ( Imec) Dual tip atomic force microscopy probe and method for producing such a probe
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US20090186050A1 (en) 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
NZ606087A (en) 2010-07-23 2014-06-27 Isconova Ab Influenza vaccine
JP5923723B2 (ja) 2011-06-02 2016-05-25 パナソニックＩｐマネジメント株式会社 人物属性推定システム、人物属性推定装置、及び人物属性推定方法
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor

Also Published As

Publication number Publication date
AU2003219839B2 (en) 2008-02-21
AR038595A1 (es) 2005-01-19
JP2009114204A (ja) 2009-05-28
JP4982514B2 (ja) 2012-07-25
US7449324B2 (en) 2008-11-11
CA2743750A1 (en) 2003-09-04
JP2012105661A (ja) 2012-06-07
WO2003072719A3 (en) 2007-09-13
CA2477234C (en) 2014-12-30
US20040005545A1 (en) 2004-01-08
US9567653B2 (en) 2017-02-14
KR20110026528A (ko) 2011-03-15
US20090246855A1 (en) 2009-10-01
US20080096263A1 (en) 2008-04-24
AR082427A2 (es) 2012-12-05
EP1485468A4 (en) 2007-01-03
EP2327418A1 (en) 2011-06-01
IL163646A0 (en) 2005-12-18
US10287640B2 (en) 2019-05-14
CN1646684A (zh) 2005-07-27
CA2477234A1 (en) 2003-09-04
TWI359868B (en) 2012-03-11
JP4553589B2 (ja) 2010-09-29
KR20050005412A (ko) 2005-01-13
KR101151822B1 (ko) 2012-06-01
US20200024672A1 (en) 2020-01-23
EP1576090A4 (en) 2008-07-16
CA2477235A1 (en) 2003-09-04
TWI344991B (en) 2011-07-11
TW201009079A (en) 2010-03-01
US20180216200A1 (en) 2018-08-02
CN1646684B (zh) 2010-10-06
CN101098958A (zh) 2008-01-02
US20090263883A1 (en) 2009-10-22
WO2003072720A3 (en) 2004-08-19
AU2003219839A1 (en) 2003-09-09
TWI405851B (zh) 2013-08-21
TW200405908A (en) 2004-04-16
JP2005518208A (ja) 2005-06-23
AU2003219837B2 (en) 2009-10-29
US11220718B2 (en) 2022-01-11
AU2003219837A1 (en) 2003-09-09
WO2003072719A2 (en) 2003-09-04
EP1576090A2 (en) 2005-09-21
MXPA04008088A (es) 2005-09-30
US20180057894A1 (en) 2018-03-01
JP4553588B2 (ja) 2010-09-29
US8841433B2 (en) 2014-09-23
EP1485468A2 (en) 2004-12-15
WO2003072720A2 (en) 2003-09-04
AR082426A2 (es) 2012-12-05
US20030232326A1 (en) 2003-12-18
US9834824B2 (en) 2017-12-05
US20170137899A1 (en) 2017-05-18
IL212138A0 (en) 2011-06-30
TW200400266A (en) 2004-01-01
TWI356848B (en) 2012-01-21
JP2006500907A (ja) 2006-01-12
KR101076102B1 (ko) 2011-10-21
US9944997B2 (en) 2018-04-17
TW200930816A (en) 2009-07-16
US20140370497A1 (en) 2014-12-18
US20200399718A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
AR038596A1 (es) Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus
US12365880B2 (en) Recombinant influenza viruses with stabilized NA
JP2022066209A (ja) Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
KR20080009101A (ko) 현탁 조류 배아 유래 줄기세포주에서의 바이러스 백신제조방법
WO2005027825A3 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
RS61993B1 (sr) Cmv vakcine
US9695444B2 (en) Vaccine prepared utilizing human parainfluenza virus type 2 vector
WO2016118642A8 (en) Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
AU2022398292A1 (en) Coronavirus vaccine
JP2017510262A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
Kim et al. Generation of G gene-deleted viral hemorrhagic septicemia virus (VHSV) and evaluation of its vaccine potential in olive flounder (Paralichthys olivaceus)
Rimmelzwaan et al. Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza?
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
AR056133A1 (es) Virus de influenza canina y composiciones relacionadas y metodos de uso
Hayasaka et al. Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses
Lawrence et al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
Kim et al. Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG)
AU2018275790B2 (en) Genetically attenuated nucleic acid vaccine
DOP2014000215A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
CA2905569A1 (en) Single high dose of modified vaccinia virus ankara induces a protective immune response in neonates and infants
Mooney et al. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration